Mayne Settles US Patent Suit With Teva Over Generic Imvexxy
ASX-listed Mayne Pharma announced on Friday another settlement related to its oestradiol vaginal insert Imvexxy, with medicines maker Teva Pharmaceuticals USA Inc. agreeing not to enter the US market with a...To view the full article, register now.
Already a subscriber? Click here to view full article